Splenic Hemangioma as a Potential Pitfall on PSMA-Targeted 18F-DCFPyL PET/CT

A 69-year-old man with biochemical recurrence after radical prostatectomy underwent 6 months of androgen deprivation therapy. Upon discontinuation of androgen deprivation therapy, serum prostate-specific antigen rose again to 0.69 ng/mL, and 18F-DCFPyL PET/CT was performed to identify the site of recurrence. However, only an intense focus of uptake in the spleen could be found. Subsequent contrast-enhanced MRI findings were pathognomonic for splenic hemangioma. Received for publication October 28, 2018; revision accepted November 3, 2018. Conflicts of interest and sources of funding: No funding or support for the work was obtained from any source. All authors report no conflicts of interest. Work was performed at Jewish General Hospital, Montreal, Quebec, Canada. Correspondence to: Guillaume Chaussé, MD, Jewish General Hospital, Department of Nuclear Medicine, G19, 3755 Cote-St-Catherine Rd, Montreal, Quebec, Canada, H3T1E2. E-mail: guillaume.chausse@mail.mcgill.ca. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

from A via a.sfakia on Inoreader http://bit.ly/2GGgrA8